HCG (Human Chorionic Gonadotropin)

Human Chorionic Gonadotropin (HCG) is a hormone naturally produced during pregnancy that has become an essential tool in male hormone optimization. While it is often called “the pregnancy hormone,” HCG has a structure very similar to luteinizing hormone (LH) and produces the same effects when administered to men. HCG is a 237-amino acid glycoprotein hormone that belongs to the glycoprotein hormone family alongside LH, follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH). These hormones share an identical alpha subunit of 92 amino acids, while their beta subunits differ and confer biological specificity. The beta subunit homology between HCG and LH is approximately 80%, which is why they bind to the same receptor and produce similar downstream effects. In men, HCG directly stimulates the Leydig cells in the testes to produce testosterone. This makes it valuable for treating hypogonadism, preserving fertility during testosterone replacement therapy (TRT), and recovering natural hormone production after anabolic steroid cycles. Unlike exogenous testosterone, which suppresses the entire hypothalamic-pituitary-gonadal (HPG) axis, HCG bypasses the pituitary and stimulates the testes directly. This maintains testicular function, prevents testicular atrophy, and preserves sperm production—all of which are typically impaired by testosterone therapy alone. HCG is FDA-approved for specific medical conditions, including male hypogonadism and certain types of infertility. It is available as a prescription medication in both pharmaceutical- grade forms (Pregnyl, Novarel) and through compounding pharmacies, although a 2019 FDA ruling significantly affected compounding pharmacy access to HCG. The hormone was first discovered in 1932 and is synthesized through recombinant technology or isolated and purified from pregnant women’s urine. For men on TRT who want to maintain fertility or testicular size, HCG has become standard practice in modern hormone optimization protocols.

How It Works

The HPG Axis and Testosterone Production

To understand why HCG is essential in male hormone optimization, it is important to understand the hypothalamic-pituitary-gonadal (HPG) axis. This axis is the driving force for testosterone production and is regulated through a negative feedback loop with both testosterone and estradiol acting as mediators of that feedback control. Under normal conditions:

• The hypothalamus releases gonadotropin-releasing hormone (GnRH)
• GnRH signals the pituitary gland to release LH and FSH
• LH stimulates the Leydig cells in the testes to produce testosterone
• FSH stimulates the Sertoli cells to support sperm production
• As testosterone and estradiol levels rise, they feed back to the hypothalamus and pituitary

to reduce GnRH, LH, and FSH output When a man takes exogenous testosterone, the brain detects elevated testosterone levels and shuts down GnRH production, which in turn reduces LH and FSH output. Without LH stimulation, the testes receive no signal to produce testosterone or sperm. The result is testicular atrophy, decreased intratesticular testosterone (ITT), and impaired fertility. Multiple scientific trials have shown that sperm counts can drop below 1 million within 3.5 months of starting testosterone therapy, and many men become azoospermic (producing zero sperm).

LH Mimicry

HCG functions by mimicking the action of LH on the testes. Because HCG and LH share approximately 80% beta subunit homology and bind to the same receptor (the LH/HCG receptor on Leydig cells), HCG literally replaces the LH that is normally produced by the pituitary:

• HCG binds to LH receptors on Leydig cells
• This stimulates testosterone synthesis within the testes
• Testosterone is produced and released into circulation
• Intratesticular testosterone levels are maintained at levels sufficient for spermatogenesis

Key Difference from LH: Half-Life

While HCG and LH have similar actions, HCG has a significantly longer half-life due to its abundance of carbohydrate residues:

• LH half-life: approximately 1 to 2 hours
• HCG half-life: approximately 24 to 36 hours

This longer duration means HCG provides sustained Leydig cell stimulation and can be dosed 2 to 3 times weekly rather than continuously, making it practical for clinical use.

HCG Does Not Stimulate FSH

While HCG effectively mimics LH, it does not stimulate FSH production or mimic FSH action. FSH is necessary for complete spermatogenesis through its action on Sertoli cells. For comprehensive fertility preservation, some protocols add recombinant FSH or utilize HMG (Human Menopausal Gonadotropin), which contains both LH-like and FSH activity.

Benefits

Testicular Preservation

The primary benefit for men on TRT:

• Maintains testicular size and fullness
• Preserves Leydig cell function and responsiveness
• Keeps the testes “primed” for natural production if TRT is ever discontinued
• Intratesticular testosterone levels are maintained, which are normally 50 to 100 times

greater than serum testosterone levels

Fertility Preservation

For men who may want children while on testosterone therapy:

• Maintains sperm production during TRT by preserving ITT levels
• Preserves fertility potential that would otherwise be severely compromised
• Can be combined with FSH for optimal spermatogenesis
• Studies show men on TRT with concurrent HCG can maintain semen parameters and

avoid azoospermia

Natural Testosterone Stimulation

As monotherapy or as an adjunct:

• Stimulates endogenous testosterone production directly at the Leydig cells
• Can increase testosterone levels by 40% to 50% in hypogonadal men
• In studies, HCG monotherapy raised testosterone from 362 ng/dL to 520 ng/dL (49.9%

increase)

• May be a viable alternative for younger men or those who want to avoid exogenous

testosterone

Recovery After Anabolic Steroids

For men cycling off androgens:

• Jump-starts testicular function after prolonged suppression
• Accelerates recovery of natural testosterone production
• Standard component of post-cycle therapy (PCT) protocols
• Case reports demonstrate full fertility restoration after prolonged anabolic steroid abuse

when combined with HMG

Sexual Function and Well-Being

Many men report:

• Improved mood and psychological well-being when testicular size is maintained
• Better ejaculate volume
• Maintained testicular sensation
• Resolution of erectile dysfunction in some cases

What the Science Shows

HCG is well-researched for male reproductive health, with robust clinical data supporting its use across multiple applications.

Coviello et al. (2005) – Journal of Clinical Endocrinology & Metabolism This landmark study established the role of low-dose HCG in TRT protocols:

• 29 men received 200 mg of testosterone enanthate weekly alongside varying doses of

HCG (0, 125, 250, or 500 IU every other day) for 3 weeks

• The 500 IU group saw a 26% increase in intratesticular testosterone
• Without HCG, intratesticular testosterone dropped by 94%
• Established that 500 IU HCG every other day is sufficient to maintain ITT at baseline

levels during testosterone therapy

Hsieh et al. (2013) – Journal of Urology Demonstrated fertility preservation on TRT with concurrent HCG:

• Hypogonadal men injected 500 IU of HCG subcutaneously three times weekly alongside

exogenous testosterone

• Men were able to maintain semen parameters throughout treatment
• No patients became azoospermic
• Some men successfully achieved pregnancies during the protocol

Zucker et al. (2022) – International Brazilian Journal of Urology HCG monotherapy study in men with “subclinical” hypogonadism:

• 20 men with hypogonadal symptoms but total testosterone above 300 ng/dL
• Average dose of 2,000 IU weekly
• Testosterone improved from 362 to 520 ng/dL (49.9% increase)

• 50% reported symptom improvement
• No adverse events reported

Kim et al. (2011) – Korean Journal of Urology HCG in hypogonadotropic hypogonadism:

• Patients received 1,500 to 2,000 IU three times weekly for 8 weeks
• Testosterone increased from 0.90 to 5.58 ng/mL
• Testicular volume increased significantly
• Penile length also increased in patients with micropenis

Bouloux et al. (2002) – Journal of Clinical Endocrinology & Metabolism Evaluated high-dose HCG in older men:

• Seniors aged 60 to 85 with partial androgen deficiency received 5,000 IU of HCG twice

weekly for 3 months

• Total and free testosterone increased significantly and stably
• No changes in physical functioning or muscle strength were observed

Fertility Restoration Case Report (2003) A bodybuilder who had taken a year off after prolonged anabolic steroid abuse presented with azoospermia and hypogonadotropic hypogonadism. After injecting 75 IU of HMG daily and 10,000 IU of HCG twice weekly for 3 months, he fully restored his fertility parameters (sperm motility, volume, and morphology), resolved erectile dysfunction within 2 months, and impregnated his partner 4 months after treatment ended.

Safety Data Across Studies

• HCG is well-tolerated across clinical studies
• The main concern is estrogen elevation due to intratesticular aromatization
• No significant changes in PSA or hematocrit in most studies
• Some studies show a slight decrease in hematocrit, which may be potentially beneficial

Dosing Protocol

HCG dosing depends on whether it is used as monotherapy, alongside TRT, or for fertility recovery. HCG is measured in International Units (IU). Doses range from 250 to 5,000 IU depending on the application. The goal is to stimulate testicular function without excessive estrogen conversion. With TRT (Maintenance Protocol) Protocol Dose Frequency Notes Low Dose 250 to 500 IU 3 times weekly Minimum effective dose Standard 500 IU 3 times weekly Most common protocol Higher Dose 1,000 IU 2 to 3 times weekly For larger individuals

The weekly total target is approximately 1,500 IU, split across doses to maintain stable intratesticular testosterone levels.

As Monotherapy

Protocol Dose Frequency Duration Standard 1,500 to 2,000 IU Weekly total Ongoing Higher 2,500 to 3,000 IU Weekly total As needed

Split into 2 to 3 injections per week for stable levels.

Post-Cycle Therapy (PCT) Phase Week Dose Frequency Notes Jump-Start 1 to 2 2,000 to 3,000 IU Every other day Restart testicular function Transition 3 to 4 1,500 IU Every other day Taper stimulation Maintenance 5+ 500 to 1,000 IU 2 to 3 times With SERM weekly

PCT protocols are often combined with a SERM (clomiphene or tamoxifen) to stimulate FSH recovery and support full HPG axis restoration.

Fertility Recovery Protocol

For men wanting to restore fertility after TRT:

• Stop TRT or continue with concurrent HCG protocol
• 500 IU every other day is the typical starting point
• Add FSH (75 IU every other day) if sperm count does not recover after 4 to 6 months
• Monitor semen analysis regularly
• For men desiring pregnancy: 500 IU every other day with optional clomiphene citrate

Draw Volumes by Vial Size

5,000 IU Vial (5 mL reconstitution = 1,000 IU/mL) Dose Volume Units on Syringe 250 IU 0.25 mL 25 units 500 IU 0.50 mL 50 units 1,000 IU 1.00 mL 100 units

10,000 IU Vial (10 mL reconstitution = 1,000 IU/mL) Dose Volume Units on Syringe 500 IU 0.50 mL 50 units 1,000 IU 1.00 mL 100 units 1,500 IU 1.50 mL Use 3 mL syringe

At 500 IU three times weekly (1,500 IU/week), a 10,000 IU vial lasts approximately 6 to 7 weeks.

Reconstitution Instructions

HCG typically comes as a lyophilized powder with bacteriostatic water provided or purchased separately. 1. Remove the plastic cap from the vial and wipe the rubber stopper with an alcohol swab. 2. Draw the appropriate volume of bacteriostatic water as specified by the product or your protocol. 3. Insert the needle through the rubber stopper at an angle. 4. Direct the stream of water down the inside wall of the vial. 5. Allow the powder to dissolve without aggressive shaking. 6. Gently swirl if needed until the solution is clear. 7. Label the vial with the date and concentration (e.g., 1,000 IU/mL). HCG dissolves readily. The solution should be clear. Discard if cloudy or discolored.

Injection Technique

HCG can be administered subcutaneously (preferred for most users) or intramuscularly. Both routes are considered equally effective. Subcutaneous injection into the abdominal fat tissue is the most common method in modern protocols.

Side Effects and Cautions

Common Side Effects

• Injection site pain or irritation
• Headache
• Fatigue
• Mood changes

Hormonal Effects

HCG stimulates intratesticular testosterone production, which can then aromatize to estrogen. Because intratesticular aromatase activity is significant, HCG can raise estrogen more than equivalent testosterone from external sources:

• Estrogen elevation (via intratesticular aromatase)
• Water retention
• Gynecomastia (breast tissue growth) if estrogen becomes excessive
• Nipple sensitivity

Management of Estrogen

If estrogen symptoms develop:

• Reduce HCG dose as the first intervention
• Add or adjust an aromatase inhibitor (anastrozole) if needed
• Monitor estradiol levels with blood work—do not assume estrogen is elevated without

testing

• Get baseline estradiol before starting HCG, then recheck at 4 to 6 weeks

Serious Concerns

• Overstimulation of the testes (rare at recommended doses)
• Allergic reactions (rare)
• Blood clots (rare, associated with high-dose protocols)

Leydig Cell Desensitization

Very high doses (greater than 5,000 IU at once) or prolonged high-dose use may lead to Leydig cell desensitization, reducing the testes’ responsiveness to stimulation. Standard therapeutic doses (500 to 1,500 IU per injection) do not typically cause this issue. This is why protocols avoid single bolus doses exceeding 5,000 IU.

Contraindications and Precautions

Who Should Avoid HCG

• Men with hormone-sensitive cancers (prostate, breast)
• Those with known allergic reactions to HCG
• Men with certain cardiovascular conditions (discuss with a physician)

Use with Care

• Men prone to high estrogen (monitor estradiol closely)
• Those with a history of gynecomastia
• Men with polycythemia or elevated hematocrit
• Anyone with cardiac, liver, or kidney conditions

Comparison to Similar Compounds

Compound Mechanism Primary Use LH Effect FSH Effect HCG LH mimic TRT adjunct Direct None HMG LH + FSH Fertility Direct Direct Gonadorelin GnRH analog TRT adjunct Stimulates Stimulates Kisspeptin-10 GnRH stimulator TRT adjunct Stimulates Moderate Clomiphene SERM PCT/testosterone Stimulates Stimulates

HCG vs. HMG

HMG (Human Menopausal Gonadotropin) contains both LH-like activity and FSH activity. For fertility optimization, HMG may be superior because it addresses both gonadotropins. HCG addresses only the LH side of the equation. When fertility is the primary goal, HMG or a combination of HCG plus recombinant FSH is often preferred.

HCG vs. Gonadorelin

Gonadorelin is a GnRH analog that acts at the pituitary to stimulate endogenous LH and FSH release. HCG bypasses the pituitary entirely and acts directly on the testes. Gonadorelin requires intact pituitary function to work; HCG does not. For men with pituitary dysfunction, HCG is the more reliable option.

HCG vs. Kisspeptin

Kisspeptin acts even further upstream than Gonadorelin, stimulating GnRH release from the hypothalamus. While Kisspeptin is considered more “physiological,” HCG is more reliable and direct. Kisspeptin is still being studied and is less commonly available.

HCG vs. Clomiphene

Clomiphene citrate is a selective estrogen receptor modulator (SERM) that blocks estrogen feedback at the hypothalamus and pituitary, thereby increasing LH and FSH release. Studies show HCG and clomiphene produce similar testosterone increases, but clomiphene works through the entire HPG axis while HCG bypasses it. Clomiphene also stimulates FSH, which HCG does not.

Success Tips

Monitor Estradiol

HCG can raise estrogen levels. Get baseline estradiol before starting, then recheck at 4 to 6 weeks. If estrogen becomes elevated:

• Symptoms include water retention, moodiness, and nipple sensitivity
• Reduce HCG dose or add/adjust aromatase inhibitor
• Do not ignore persistent symptoms
• Do not assume estrogen is high without blood work confirmation

Consistency Is Key

HCG works best with consistent dosing. Split the weekly dose into 2 to 3 injections to maintain stable stimulation. Erratic dosing leads to fluctuating hormone levels and suboptimal results.

Pair with a Comprehensive Protocol

HCG is often part of a larger TRT or hormone optimization protocol. Work with a knowledgeable provider to integrate HCG with testosterone, estrogen management, and overall health monitoring. HCG alone does not address all aspects of hormonal health.

Storage Matters

HCG degrades if not stored properly. Keep reconstituted HCG refrigerated and use within the timeframe specified (typically 30 to 60 days). Do not freeze reconstituted HCG. Improper storage is one of the most common reasons for reduced efficacy.

Realistic Expectations

HCG prevents testicular atrophy and maintains some fertility, but it cannot fully replicate natural function while on TRT. Some degree of HPG axis suppression is inevitable with exogenous testosterone. HCG minimizes rather than eliminates the impact.

Foundation First

Hormonal optimization begins with the fundamentals: adequate sleep, stress management, whole food nutrition, and regular exercise. These factors directly influence testosterone production, estrogen metabolism, and overall endocrine function. HCG is a tool that works best within an optimized lifestyle.

Storage and Handling

Before Reconstitution

• Store powder at room temperature or refrigerated (per manufacturer instructions).
• Protect from light.
• Stable for extended periods before reconstitution.
• Do not use past the expiration date.

After Reconstitution

• Refrigerate at 2°C to 8°C.
• Use within 30 to 60 days (check specific product guidelines).
• Do not freeze reconstituted HCG.
• Discard if the solution becomes cloudy or discolored.
• Keep the stopper clean between uses.

HCG is relatively sensitive to heat and light. Proper storage is essential for maintaining potency.

Legal Status

United States: HCG is a prescription medication FDA-approved for specific conditions, including male hypogonadism and certain types of infertility. Pharmaceutical-grade HCG (Pregnyl, Novarel) is available through retail pharmacies with a prescription. A 2019 FDA ruling restricted compounding pharmacy production of HCG by reclassifying it as a biologic under the Biologics Price Competition and Innovation Act (BPCIA), making it more difficult to obtain through some compounding sources. However, some compounding pharmacies have found pathways to continue production.

Frequently Asked Questions

Why is HCG used with TRT? TRT suppresses natural testosterone production by shutting down the HPG axis. Without HCG, the testes receive no stimulation, leading to atrophy, decreased intratesticular testosterone, and impaired fertility. HCG directly stimulates the testes regardless of axis suppression, maintaining testicular function and preserving spermatogenesis. Can I use HCG instead of TRT? For some men with secondary hypogonadism, HCG monotherapy can effectively raise testosterone levels. Studies show it can increase testosterone by approximately 50%. However, it typically does not raise testosterone as high as TRT. It is often used as an alternative when fertility preservation is the priority or for younger men who want to avoid exogenous testosterone. Will HCG completely preserve my fertility on TRT? HCG significantly improves fertility preservation compared to TRT alone, but it does not guarantee complete preservation. For optimal fertility outcomes, some protocols add FSH (as HMG or recombinant FSH). Sperm counts may still be lower than baseline even with HCG, though studies show it prevents azoospermia in most cases. Why does HCG raise estrogen? HCG stimulates testosterone production within the testes. This intratesticular testosterone can be converted to estrogen by aromatase enzymes present in the testicular tissue. Because intratesticular aromatase activity is significant, HCG can raise estrogen more than equivalent testosterone from external sources. How do I manage HCG estrogen side effects? Monitor estradiol levels with blood work. If elevated with symptoms, options include reducing HCG dose or adding an aromatase inhibitor (anastrozole). Do not assume estrogen is high without testing. Get baseline estradiol before starting, then recheck at 4 to 6 weeks. Is HCG still available after the 2019 FDA ruling? Yes, but access has changed. Pharmaceutical-grade HCG (Pregnyl, Novarel) is still available through retail pharmacies with a prescription. Some compounding pharmacies can no longer produce it under the new biologics classification. Availability varies by location and pharmacy. Work with a knowledgeable provider to identify current access options. What is the difference between HCG and HMG? HCG mimics only LH and directly stimulates the Leydig cells to produce testosterone. HMG (Human Menopausal Gonadotropin) contains both LH-like and FSH activity, stimulating both Leydig and Sertoli cells. For fertility purposes, HMG may be superior because it supports complete spermatogenesis. HCG is more commonly used for testicular preservation and testosterone support during TRT. Can HCG cause Leydig cell desensitization? Yes, but only at very high doses (greater than 5,000 IU per injection) or with prolonged high- dose use. Standard therapeutic doses of 500 to 1,500 IU per injection do not typically cause desensitization. Protocols that avoid single bolus doses exceeding 5,000 IU are considered safe for long-term use.

References

1. Coviello AD, Matsumoto AM, Bremner WJ, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. Journal of Clinical Endocrinology & Metabolism. 2005;90(5):2595–2602. 2. Lee JA, Ramasamy R. Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men. Translational Andrology and Urology. 2018;7(Suppl 3):S348–S352. 3. Zucker I, Manschreck R, Boorjian SA, et al. Human chorionic gonadotropin monotherapy for the treatment of hypogonadal symptoms in men with total testosterone greater than 300 ng/dL. International Brazilian Journal of Urology. 2022;48(5):884–890. 4. Kim ED, Crosnoe L, Bar-Chama N, Khera M, Lipshultz LI. The treatment of hypogonadism in men of reproductive age. Fertility and Sterility. 2013;99(3):718–724. 5. Madhusoodanan V, Shah P, Joshi A. Effect of human chorionic gonadotropin on testosterone levels in hypogonadal men. International Brazilian Journal of Urology. 2019;45(3):457–464. 6. Hsieh TC, Pastuszak AW, Hwang K, Lipshultz LI. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. Journal of Urology. 2013;189(2):647–650. 7. Bouloux PM, Warne DW, Loumaye E. Efficacy and safety of recombinant human follicle- stimulating hormone in men with isolated hypogonadotropic hypogonadism. Fertility and Sterility. 2002;77(2):270–273. 8. Cole LA. Biological functions of hCG and hCG-related molecules. Reproductive Biology and Endocrinology. 2010;8:102. 9. Santi D, Crépieux P, Bhagat K, et al. Follicle-stimulating hormone (FSH) action on spermatogenesis: a focus on physiological and therapeutic roles. Journal of Clinical Medicine. 2020;9(4):1014. 10. Crosnoe LE, Grober E, Ohl D, Kim ED. Exogenous testosterone: a preventable cause of male infertility. Translational Andrology and Urology. 2013;2(2):106–113.